Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2011, Article ID 596898, 6 pages
http://dx.doi.org/10.1155/2011/596898
Research Article

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial

1Mental Health and Neurodegeneration Research Group, The University of Manchester, Manchester M13 9PL, UK
2National Drug Evidence Centre (NDEC), School of Community Based Medicine, The University of Manchester, Manchester M15 6SZ, UK

Received 5 November 2009; Revised 24 August 2010; Accepted 4 November 2010

Academic Editor: D. Naber

Copyright © 2011 Ahmed Mahmoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Kelly and R. R. Conley, “A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia,” Psychoneuroendocrinology, vol. 31, no. 3, pp. 340–346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Dossenbach, A. Hodge, M. Anders et al., “Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation,” International Journal of Neuropsychopharmacology, vol. 8, no. 2, pp. 195–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Smith, V. O'Keane, and R. Murray, “Sexual dysfunction in patients taking conventional antipsychotic medication,” British Journal of Psychiatry, vol. 181, pp. 49–55, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Üçok, C. İncesu, T. Aker, and Ş. Erkoç, “Sexual dysfunction in patients with schizophrenia on antipsychotic medication,” European Psychiatry, vol. 22, no. 5, pp. 328–333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Assalian, R. Fraser, R. Tempier, and D. Cohen, “Sexuality and quality of life of patients with schizophrenia,” International Journal of Psychiatry in Clinical Practice, vol. 4, no. 1, pp. 29–33, 2000. View at Google Scholar · View at Scopus
  6. M. Olfson, T. Uttaro, W. H. Carson, and E. Tafesse, “Male sexual dysfunction and quality of life in schizophrenia,” Journal of Clinical Psychiatry, vol. 66, no. 3, pp. 331–338, 2005. View at Google Scholar · View at Scopus
  7. J. Peuskens, P. Sienaert, and M. De Hert, “Sexual dysfunction: the unspoken side effect of antipsychotics,” European Psychiatry, vol. 13, supplement 1, pp. 23s–30s, 1998. View at Google Scholar · View at Scopus
  8. M. M. Berner, M. Hagen, and L. Kriston, “Management of sexual dysfunction due to antipsychotic drug therapy,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Lambert, P. Conus, P. Eide et al., “Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence,” European Psychiatry, vol. 19, no. 7, pp. 415–422, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. E. Finn, J. M. Bailey, R. T. Schultz, and R. Faber, “Subjective utility ratings of neuroleptics in treating schizophrenia,” Psychological Medicine, vol. 20, no. 4, pp. 843–848, 1990. View at Google Scholar · View at Scopus
  11. W. K. H. Fakhoury, D. Wright, and M. Wallace, “Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline,” International Clinical Psychopharmacology, vol. 16, no. 3, pp. 153–162, 2001. View at Google Scholar · View at Scopus
  12. A. J. Cutler, “Sexual dysfunction and antipsychotic treatment,” Psychoneuroendocrinology, vol. 28, supplement 1, pp. 69–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. D. L. Kelly and R. R. Conley, “Sexuality and schizophrenia: a review,” Schizophrenia Bulletin, vol. 30, no. 4, pp. 767–779, 2004. View at Google Scholar · View at Scopus
  14. D. O. Perkins, “Predictors of noncompliance in patients with schizophrenia,” Journal of Clinical Psychiatry, vol. 63, no. 12, pp. 1121–1128, 2002. View at Google Scholar · View at Scopus
  15. S. Smith, “Effects of antipsychotics on sexual and endocrine function in women: implications for clinical practice,” Journal of Clinical Psychopharmacology, vol. 23, no. 3, pp. S27–S32, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Hamner, “The effects of atypical antipsychotics on serum prolactin levels,” Annals of Clinical Psychiatry, vol. 14, no. 3, pp. 163–173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Knegtering, R. van den Bosch, S. Castelein, R. Bruggeman, S. Sytema, and J. van Os, “Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin?” Psychoneuroendocrinology, vol. 33, no. 6, pp. 711–717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Malik, “Sexual dysfunction in schizophrenia,” Current Opinion in Psychiatry, vol. 20, no. 2, pp. 138–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Baggaley, “Sexual dysfunction in schizophrenia: focus on recent evidence,” Human Psychopharmacology, vol. 23, no. 3, pp. 201–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. M. Haddad and S. G. Sharma, “Adverse effects of atypical antipsychotics: differential risk and clinical implications,” CNS Drugs, vol. 21, no. 11, pp. 911–936, 2007. View at Google Scholar · View at Scopus
  21. A. M. Ghadirian, G. Chouinard, and L. Annable, “Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients,” Journal of Nervous and Mental Disease, vol. 170, no. 8, pp. 463–467, 1982. View at Google Scholar · View at Scopus
  22. B. G. Soares, M. Fenton, and P. Chue, “Sulpiride for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001162, 2000. View at Google Scholar · View at Scopus
  23. R. Arakawa, M. Okumura, H. Ito et al., “Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia,” Journal of Clinical Psychiatry, vol. 71, no. 9, pp. 1131–1137, 2010. View at Publisher · View at Google Scholar
  24. P. M. Haddad and A. Wieck, “Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management,” Drugs, vol. 64, no. 20, pp. 2291–2314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Bushe, D. Yeomans, T. Floyd, and S. M. Smith, “Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics,” Journal of Psychopharmacology, vol. 22, supplement 2, pp. 56–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Falkai, T. Wobrock, J. Lieberman et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia—part 1: acute treatment of schizophrenia,” World Journal of Biological Psychiatry, vol. 6, no. 3, pp. 132–191, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Hummer and J. Huber, “Hyperprolactinaemia and antipsychotic therapy in schizophrenia,” Current Medical Research and Opinion, vol. 20, no. 2, pp. 189–197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Bitter, B. R. Basson, and M. R. Dossenbach, “Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients,” International Clinical Psychopharmacology, vol. 20, no. 1, pp. 19–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Dossenbach, Y. Dyachkova, S. Pirildar et al., “Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study,” European Psychiatry, vol. 21, no. 4, pp. 251–258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Lambert, J. M. Haro, D. Novick et al., “Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European schizophrenia out-patient health outcomes study,” Acta Psychiatrica Scandinavica, vol. 111, no. 3, pp. 232–243, 2005. View at Publisher · View at Google Scholar
  31. J. Bobes, M. P. García-Portilla, J. Rejas et al., “Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study,” Journal of Sex and Marital Therapy, vol. 29, no. 2, pp. 125–147, 2003. View at Google Scholar · View at Scopus
  32. M. J. Byerly, P. A. Nakonezny, B. M. Bettcher, T. Carmody, R. Fisher, and A. J. Rush, “Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine,” Schizophrenia Research, vol. 86, no. 1–3, pp. 244–250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Knegtering, S. Castelein, H. Bous et al., “A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning,” Journal of Clinical Psychopharmacology, vol. 24, no. 1, pp. 56–61, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Hanssens, G. L'Italien, J. Y. Loze, R. N. Marcus, M. Pans, and W. Kerselaers, “The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913),” BMC Psychiatry, vol. 8, article no. 95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Mir, K. Shivakumar, R. J. Williamson, V. McAllister, V. O'Keane, and K. J. Aitchison, “Change in sexual dysfunction with aripiprazole: a switching or add-on study,” Journal of Psychopharmacology, vol. 22, no. 3, pp. 244–253, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. B. Jones, T. R. E. Barnes, L. Davies et al., “Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1),” Archives of General Psychiatry, vol. 63, no. 10, pp. 1079–1087, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. W. Lewis, T. R. E. Barnes, L. Davies et al., “Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia,” Schizophrenia Bulletin, vol. 32, no. 4, pp. 715–723, 2006. View at Publisher · View at Google Scholar
  38. S. W. Lewis, L. Davies, P. B. Jones et al., “Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment,” Health Technology Assessment, vol. 10, no. 17, 2006. View at Google Scholar · View at Scopus
  39. L. R. Derogatis, “The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report,” Journal of Sex and Marital Therapy, vol. 23, no. 4, pp. 291–304, 1997. View at Google Scholar · View at Scopus
  40. D. W. Heinrichs, T. E. Hanlon, and W. T. Carpenter, “The quality of life scale: an instrument for rating the schizophrenic deficit syndrome,” Schizophrenia Bulletin, vol. 10, no. 3, pp. 388–398, 1984. View at Google Scholar · View at Scopus
  41. A. F. Lehman, “Measures of quality of life among persons with severe and persistent mental disorders,” Social Psychiatry and Psychiatric Epidemiology, vol. 31, no. 2, pp. 78–88, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Cramer, R. Rosenheck, W. Xu, W. Henderson, J. Thomas, and D. Charney, “Detecting improvement in quality of life and symptomatology in schizophrenia,” Schizophrenia Bulletin, vol. 27, pp. 227–234, 2001. View at Google Scholar
  43. D. Aizenberg, Z. Zemishlany, P. Dorfman-Etrog, and A. Weizman, “Sexual dysfunction in male schizophrenic patients,” Journal of Clinical Psychiatry, vol. 56, no. 4, pp. 137–141, 1995. View at Google Scholar · View at Scopus
  44. D. Novick, J. M. Haro, E. Perrin, D. Suarez, and J. M. Texeira, “Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study,” European Neuropsychopharmacology, vol. 19, no. 8, pp. 542–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Gourevitch, S. Abbadi, and J. D. Guelfi, “Quality of life in schizophrenics with and without the deficit syndrome,” European Psychiatry, vol. 19, no. 3, pp. 172–174, 2004. View at Publisher · View at Google Scholar · View at Scopus